Mayne Pharma announces legal settlement
Released
Released
Announcement PDF
ASX Announcement
MAYNE PHARMA ANNOUNCES LEGAL SETTLEMENT
28 September 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma or the
Company) (ASX: MYX), today announces an agreement to resolve the civil complaint brought by the
attorneys general of 49 US states and territories (‘States’). This complaint is one of the legacy civil
actions that arose in response to an industry-wide investigation into the US generic pharmaceutical
sector that was initiated in March 2016 by the U.S. Department of Justice, Antitrust Division. As
announced in November 2023, the Antitrust Division’s investigation related to Mayne Pharma
appears to be closed.
Under the settlement agreement, Mayne Pharma will make a one-time payment of US$0.65 million
in full and final settlement of the States' claims. The settlement is made without any admission of
liability or wrongdoing of any sort by Mayne Pharma.
The decision to settle reflects a pragmatic commercial judgement rather than any change in the
Company's view of the claims, which it has consistently and strongly defended. Resolving the States'
action removes a meaningful source of legal costs, management distraction and uncertainty.
The ongoing obligations under the settlement are limited and administrative in nature. Beyond the
settlement payment, Mayne Pharma is only required to confirm to the nominated representative
State Attorney General that it maintains an antitrust compliance policy (which is in place today) and
to provide annual notices describing the nature of and continued compliance with that policy for a
period of two years. The agreement imposes no restrictions on how Mayne Pharma conducts its
business, and the sole consequence of an inadvertent failure to provide the aforementioned notice
is a one-year extension of the notice period, with no financial penalty attached.
The settlement agreement is subject to final court approval. Mayne Pharma will keep shareholders
and the market informed in accordance with its continuous disclosure obligations as the matter
progresses to finalisation.
Click here to view the announcement on Investor Hub.
For further information contact:
Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com
Authorised for release to the ASX by the Board Chair.
Follow us on LinkedIn
ASX Announcement
Page 2
About Mayne Pharma
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising
novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma
is a leader in dermatology and women’s health in the United States and also provides contract
development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track
record of innovation and success in developing new oral drug delivery systems. These technologies
have been successfully commercialised in numerous products that continue to be marketed around
the world. To learn more about Mayne Pharma, please visit maynepharma.com.
Share your feedback
Discover